MCID: STR015
MIFTS: 35

Stereotypic Movement Disorder

Categories: Mental diseases

Aliases & Classifications for Stereotypic Movement Disorder

MalaCards integrated aliases for Stereotypic Movement Disorder:

Name: Stereotypic Movement Disorder 12 44 15 73
Stereotyped Repetitive Movements 12
Stereotypy Habit Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2303
ICD10 33 F98.4
ICD9CM 35 307.3
MeSH 44 D019956
SNOMED-CT 68 5507002
UMLS 73 C0038273

Summaries for Stereotypic Movement Disorder

Disease Ontology : 12 A specific developmental disorder that is characterized by repeated, rhythmic, purposeless movements or activities such as head banging, nail biting, or body rocking.

MalaCards based summary : Stereotypic Movement Disorder, also known as stereotyped repetitive movements, is related to trichotillomania and parasomnia, sleep bruxism type, and has symptoms including tremor, clonus and myoclonus. An important gene associated with Stereotypic Movement Disorder is PRL (Prolactin). The drugs Methylphenidate and Guanfacine have been mentioned in the context of this disorder. Affiliated tissues include skin, brain and testes, and related phenotype is behavior/neurological.

Wikipedia : 76 Stereotypic movement disorder (SMD) is a motor disorder with onset in childhood involving repetitive,... more...

Related Diseases for Stereotypic Movement Disorder

Diseases related to Stereotypic Movement Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 36)
# Related Disease Score Top Affiliating Genes
1 trichotillomania 30.2 ABCB6 CLNK PRL SLITRK1
2 parasomnia, sleep bruxism type 11.0
3 spasmus nutans 10.3
4 movement disease 10.2
5 impulse control disorder 10.1 CLNK SLITRK1
6 kleptomania 10.1 ABCB6 SLITRK1
7 paraphilia disorder 10.1 ABCB6 PRL
8 social phobia 10.1 CCK PRL
9 pancreatic steatorrhea 10.0 CCK TAC1
10 global developmental delay, absent or hypoplastic corpus callosum, and dysmorphic facies 10.0
11 brain injury 10.0
12 epilepsy 10.0
13 encephalopathy 10.0
14 meningoencephalitis 10.0 MECP2 TAC1
15 spinocerebellar degeneration 10.0 NPY PRL
16 intermittent explosive disorder 10.0 NPY PRL
17 fibromyalgia 10.0 NPY PRL
18 pain agnosia 10.0 CCK TAC1
19 agnosia 10.0 CCK TAC1
20 irritable bowel syndrome 9.9 CCK TAC1
21 substance abuse 9.9 NPY PRL
22 headache 9.9 CCK TAC1
23 autonomic nervous system disease 9.9 NPY TAC1
24 indeterminate leprosy 9.9 NPY TAC1
25 gallbladder disease 9.9 CCK MECP2
26 causalgia 9.9 NPY TAC1
27 complex regional pain syndrome 9.9 NPY TAC1
28 acquired metabolic disease 9.8 NPY PRL
29 specific developmental disorder 9.8 CCK MECP2 TAC1
30 bulimia nervosa 9.8 CCK NPY
31 anorexia nervosa 9.8 CCK NPY PRL
32 disease of mental health 9.8 CCK MECP2
33 eating disorder 9.8 CCK NPY
34 constipation 9.7 CCK NPY TAC1
35 prader-willi syndrome 9.7 CCK MECP2 NPY
36 schizophrenia 9.5 CCK MECP2 NPY PRL

Graphical network of the top 20 diseases related to Stereotypic Movement Disorder:



Diseases related to Stereotypic Movement Disorder

Symptoms & Phenotypes for Stereotypic Movement Disorder

UMLS symptoms related to Stereotypic Movement Disorder:


tremor, clonus, myoclonus, involuntary movements, athetosis, muscular fasciculation, recurrent muscle twitches (symptom)

MGI Mouse Phenotypes related to Stereotypic Movement Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.1 CCK MECP2 NPY PRL SLITRK1 TAC1

Drugs & Therapeutics for Stereotypic Movement Disorder

Drugs for Stereotypic Movement Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 115)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylphenidate Approved, Investigational Phase 4,Phase 3 113-45-1 4158
2
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
3
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
4 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
5 Antihypertensive Agents Phase 4
6 Adrenergic Agents Phase 4,Phase 3,Phase 2
7 Adrenergic alpha-Agonists Phase 4
8 Adrenergic alpha-2 Receptor Agonists Phase 4
9 Adrenergic Agonists Phase 4
10 Excitatory Amino Acid Antagonists Phase 4,Not Applicable
11 Protective Agents Phase 4,Phase 2
12 Anticonvulsants Phase 4,Phase 2,Not Applicable
13 Excitatory Amino Acids Phase 4,Not Applicable
14 Neuroprotective Agents Phase 4
15
Sertraline Approved Phase 3,Phase 2 79617-96-2 68617
16
Aripiprazole Approved, Investigational Phase 3,Phase 2 129722-12-9 60795
17
Dopamine Approved Phase 3,Phase 2 51-61-6, 62-31-7 681
18
Ethanol Approved Phase 3,Phase 2 64-17-5 702
19
Acamprosate Approved, Investigational Phase 3,Phase 2 77337-76-9 71158
20 Brexpiprazole Approved, Investigational Phase 3 913611-97-9
21 Serotonin Agents Phase 3,Phase 2
22 Antidepressive Agents Phase 3,Phase 2
23 Neurotransmitter Uptake Inhibitors Phase 3,Phase 2
24 Serotonin Uptake Inhibitors Phase 3,Phase 2
25 Psychotropic Drugs Phase 3,Phase 2,Not Applicable
26 Tranquilizing Agents Phase 3,Phase 2,Not Applicable
27 Antipsychotic Agents Phase 3,Phase 2
28 Central Nervous System Depressants Phase 3,Phase 2,Not Applicable
29 Serotonin 5-HT2 Receptor Antagonists Phase 3
30 Paliperidone Palmitate Phase 3
31 Serotonin Antagonists Phase 3
32 Dopamine Antagonists Phase 3
33 Dopamine Agents Phase 3,Phase 2
34 Dopamine D2 Receptor Antagonists Phase 3
35 Atomoxetine Hydrochloride Phase 3
36 Dopamine Uptake Inhibitors Phase 3
37 Central Nervous System Stimulants Phase 3
38 Quetiapine Fumarate Phase 3 111974-72-2
39 Dopamine agonists Phase 3,Phase 2
40 Pharmaceutical Solutions Phase 3,Phase 2
41
Serotonin Investigational, Nutraceutical Phase 3,Phase 2 50-67-9 5202
42
Desipramine Approved, Investigational Phase 2 50-47-5 2995
43
Valproic Acid Approved, Investigational Phase 2 99-66-1 3121
44 Orange Approved Phase 2
45
Oxytocin Approved, Vet_approved Phase 2 50-56-6 439302 53477758
46
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
47
Citalopram Approved Phase 2 59729-33-8 2771
48
Zinc Approved, Investigational Phase 2 7440-66-6
49
Mecasermin Approved, Investigational Phase 2 68562-41-4
50
Metformin Approved Phase 2 657-24-9 14219 4091

Interventional clinical trials:

(show top 50) (show all 91)
# Name Status NCT ID Phase Drugs
1 Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder Completed NCT01238575 Phase 4 extended-release guanfacine
2 Riluzole in Fragile X Syndrome Completed NCT00895752 Phase 4 Riluzole
3 Repetitive Behavior Disorders in People With Severe Mental Retardation Unknown status NCT00491478 Phase 3 sertraline
4 Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders Completed NCT00870727 Phase 3 Aripiprazole oral product;Placebo oral capsule
5 Use of Acupuncture In Children With Autistic Spectrum Disorder Completed NCT00346736 Phase 3
6 Folinic Acid in Autism Completed NCT03771560 Phase 2, Phase 3 folinic acid
7 Study of Paliperidone ER in Adolescents and Young Adults With Autism Completed NCT00549562 Phase 3 Paliperidone ER
8 Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD) Completed NCT00365859 Phase 3 Aripiprazole
9 Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism Completed NCT00498173 Phase 3 Atomoxetine;Placebo
10 A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms Completed NCT00541346 Phase 3 Methylphenidate Transdermal System
11 Acamprosate in Youth With Fragile X Syndrome Completed NCT01300923 Phase 3 Acamprosate
12 Brexpiprazole in Patients With Acute Schizophrenia Completed NCT01810380 Phase 3 Placebo;Brexpiprazole;Quetiapine extended release
13 Study of Acamprosate in Autism Recruiting NCT01813318 Phase 2, Phase 3 Acamprosate;Placebo
14 Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Autistic Disorder Recruiting NCT03487770 Phase 3 Aripiprazole Oral Solution;Placebo Oral Solution
15 Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development Not yet recruiting NCT03780673 Phase 2, Phase 3 Simvastatin;Rifaximin;Placebo of Simvastatin;Placebo of Rifaximin
16 Reducing Internalized Stigma in People With Serious Mental Illness Completed NCT01259427 Phase 2
17 Pilot Study of the Effects of the Desipramine on the Neurovegetative Parameters of the Child With Rett Syndrome Completed NCT00990691 Phase 2 Administration of a high dose of desipramine;Administration of a low dose of desipramine;Administration of a placebo
18 Divalproex Sodium vs. Placebo in Childhood/Adolescent Autism Completed NCT00211757 Phase 2 Divalproex sodium;Placebo
19 Short-term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz Syndrome Completed NCT00114634 Phase 2
20 A Prospective Open-label Study of Aripiprazole in Fragile X Syndrome Completed NCT00420459 Phase 2 Aripiprazole
21 Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder Completed NCT01694667 Phase 2 Omega-3 Fatty Acids
22 Intranasal Oxytocin in the Treatment of Autism Completed NCT00490802 Phase 2 Oxytocin;Placebo
23 A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders Completed NCT00453180 Phase 2 N-acetylcysteine;Placebo
24 Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1) Completed NCT00086645 Phase 2 citalopram hydrobromide
25 Intranasal Oxytocin Treatment for Social Deficits in Children With Autism Completed NCT01624194 Phase 2 Oxytocin nasal spray;Placebo
26 Treatment of Rett Syndrome With Recombinant Human IGF-1 Completed NCT01777542 Phase 2 Recombinant Human Insulin Growth Factor 1 (rhIGF-1);Placebo
27 Essential Oils for Enhancing QOL in ASD Completed NCT02543203 Phase 2
28 Metformin in Children and Adults With Fragile X Syndrome Recruiting NCT03722290 Phase 2 Metformin
29 Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder Recruiting NCT02909959 Phase 2 Sulforaphane;Placebo
30 A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder Recruiting NCT03664232 Phase 2 JNJ-42165279;Placebo
31 A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome Recruiting NCT03569631 Phase 2 BPN14770;Placebo
32 Arbaclofen in Children and Adolescents With ASD Not yet recruiting NCT03682978 Phase 2 Arbaclofen;Placebo
33 Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis Suspended NCT00004300 Phase 2 bromocriptine;sertraline hydrochloride
34 Osteoconduction Potential of an Injectable Calcium Phosphate in Orthopaedic Surgery in Fillings of Osseous Defects Unknown status NCT00206791 Not Applicable
35 Effects of an Educational Program on Depression Literacy and Stigma Among Secondary School Students in Jazan City Unknown status NCT02663180 Not Applicable
36 The Relationship Between Metamemory and Memory in Old Age Unknown status NCT02113345 Not Applicable
37 CORAL Study: Proof of Concept Trial Unknown status NCT01379014 Not Applicable
38 Cerebral Activity Related to Primary Motor Stereotypies in Children: An EEG Study. Completed NCT01037361
39 Use of Functional Behavioral Assessments to Evaluate Stereotypy and Repetitive Behaviors in a Double-blind, Placebo Controlled Trials of Various Medications Used to Treat Children With Autism. Completed NCT00211770
40 Ending Self Stigma for PTSD Completed NCT02734212 Not Applicable
41 A Pre and Post Test Intervention Design to Prevent Abortion and Contraceptive-use Stigma Among School Youths in Kenya Completed NCT03065842 Not Applicable
42 The Impact of Teacher Nonverbal Behaviors on Children's Intergroup Attitudes and Mental Health Completed NCT03584230 Not Applicable
43 Use of a Visual Pedagogy and Structure With Children With Autism for Routine Physical Exams Completed NCT03232775 Not Applicable
44 An Intervention to Improve Communication Between Physicians and Minority Patients With Hypertension Completed NCT01037920 Not Applicable
45 Study Evaluating the Nasopharyngeal Carriage in Healthy Children Completed NCT00768833
46 Study of the Preliminary Effect of TEVAW: a Program to Address Intimate Partner Violence in Northern Tanzania Completed NCT02434796 Not Applicable
47 LINE: Treatment Patterns in postmenopausaL Women With Hormone Receptor Positive Breast Cancer Completed NCT01561443
48 Effectiveness of a Dissonance-Based Eating Disorder Prevention Program (The Body Project II) Completed NCT00663754 Not Applicable
49 Using the Prevent-Teach-Reinforce Model to Reduce Problem Behaviors in Children With Autism Spectrum Disorders Completed NCT02153203 Not Applicable
50 Comparative Evaluation of Gabapentine and Occlusal Splint in the Management of Sleep Bruxism Completed NCT01255878 Not Applicable Gabapentine

Search NIH Clinical Center for Stereotypic Movement Disorder

Cochrane evidence based reviews: stereotypic movement disorder

Genetic Tests for Stereotypic Movement Disorder

Anatomical Context for Stereotypic Movement Disorder

MalaCards organs/tissues related to Stereotypic Movement Disorder:

41
Skin, Brain, Testes

Publications for Stereotypic Movement Disorder

Articles related to Stereotypic Movement Disorder:

(show all 13)
# Title Authors Year
1
Stereotypic movement disorder: a case for Procrustes? ( 25039962 )
2014
2
Cheek-biting disorder: another stereotypic movement disorder? ( 21889295 )
2011
3
Trichotillomania (hair pulling disorder), skin picking disorder, and stereotypic movement disorder: toward DSM-V. ( 20533371 )
2010
4
Stereotypic movement disorder: easily missed. ( 20187883 )
2010
5
Escitalopram treatment of stereotypic movement disorder in an adolescent with mitochondrial disorder and mental retardation. ( 19519269 )
2009
6
Is trichotillomania a stereotypic movement disorder? An analysis of body-focused repetitive behaviors in people with hair-pulling. ( 19034750 )
2008
7
Trichotillomania, stereotypic movement disorder, and related disorders. ( 17880861 )
2007
8
Opiate sensitivity test in patients with stereotypic movement disorder and trichotillomania. ( 12369265 )
2002
9
Stereotypic movement disorder after acquired brain injury. ( 12097226 )
2002
10
Characteristics of stereotypic movement disorder and self-injurious behavior assessed with the Diagnostic Assessment for the Severely Handicapped (DASH-II). ( 9403928 )
1997
11
Stereotypic movement disorder. ( 9164434 )
1997
12
DSM-IV stereotypic movement disorder: persistence of stereotypies of infancy in intellectually normal adolescents and adults. ( 8617696 )
1996
13
A case of stereotyped repetitive movements. ( 21927255 )
1987

Variations for Stereotypic Movement Disorder

Expression for Stereotypic Movement Disorder

Search GEO for disease gene expression data for Stereotypic Movement Disorder.

Pathways for Stereotypic Movement Disorder

GO Terms for Stereotypic Movement Disorder

Cellular components related to Stereotypic Movement Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.35 CCK NPY PRL SLITRK1 TAC1
2 extracellular space GO:0005615 9.02 CCK MECP2 NPY PRL TAC1

Biological processes related to Stereotypic Movement Disorder according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.65 CCK NPY PRL
2 neuropeptide signaling pathway GO:0007218 9.51 NPY TAC1
3 axonogenesis GO:0007409 9.49 CCK SLITRK1
4 memory GO:0007613 9.46 CCK MECP2
5 positive regulation of synapse assembly GO:0051965 9.43 MECP2 SLITRK1
6 regulation of blood pressure GO:0008217 9.4 NPY TAC1
7 synapse assembly GO:0007416 9.37 MECP2 SLITRK1
8 chemical synaptic transmission GO:0007268 9.33 MECP2 NPY TAC1
9 sensory perception of pain GO:0019233 9.32 MECP2 TAC1
10 visual learning GO:0008542 9.26 CCK MECP2
11 long-term memory GO:0007616 8.96 MECP2 TAC1
12 multicellular organismal response to stress GO:0033555 8.62 MECP2 PRL

Molecular functions related to Stereotypic Movement Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 8.96 CCK NPY
2 hormone activity GO:0005179 8.8 CCK NPY PRL

Sources for Stereotypic Movement Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....